Aandeel ITCI INTRA-CELLULAR THERAPIES, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Intra-Cellular Therapies, Inc.

Aandelen

ITCI

US46116X1019

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 25-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
72,13 USD -1,35% Intraday-grafiek van Intra-Cellular Therapies, Inc. +0,18% +0,71%
23/04 INTRA-CELLULAR THERAPIES, INC. : Canaccord Genuity nog altijd een koopadvies ZM
23/04 INTRA-CELLULAR THERAPIES, INC. : Een koopadvies van Needham & Co. ZM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
Intra-Cellular Therapies Prices $500 Million Stock Offering
Intra-Cellular Therapies Prices Public Offering of Common Stock
Intra-Cellular Therapies Launches $500 Million Public Offering of Stock; Shares Edge Lower in Late Trade
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Sector Update: Health Care Stocks Higher Late Afternoon
Top Midday Gainers
US Stocks Lacking Direction Prior to Powell Remarks, Investors Looking for Signs of Future Rate Cuts by Federal Reserve
Intra-Cellular Therapies Stock Jumps After Major Depressive Disorder Treatment Study Shows Positive Results
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Intra-Cellular Therapies, Inc. Announces Executive Changes
Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Intra-Cellular Therapies Insider Sold Shares Worth $1,458,650, According to a Recent SEC Filing
Intra-Cellular Therapies Insider Sold Shares Worth $1,808,253, According to a Recent SEC Filing
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ITCI
  4. Nieuws Intra-Cellular Therapies, Inc.
  5. Andere talen